Department of Pediatrics, Division of Cardiology Le Bonheur Children's Hospital and The Heart Institute, University of Tennessee Health Science Center, College of Medicine, 49 N. Dunlap Street, 3rd Floor, Faculty Office Building, Memphis, TN, 38105, USA.
Cardio-Hema-Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.
J Thromb Thrombolysis. 2021 May;51(4):846-853. doi: 10.1007/s11239-020-02273-7. Epub 2020 Sep 12.
Cardiac mortality is the leading cause of death secondary to malignancy in survivors of cancer. The field of cardio-oncology is dedicated to identifying and, if possible, modifying risk factors that contribute to significant cardiac morbidity and mortality. Many risk factors for the development of cancer-related cardiotoxicity overlap with risk factors in cardiovascular disease such as hypertension, obesity, dyslipidemia, and diabetes among others. These risk factors are usually modifiable while others such as genetics, type of malignancy, and need for chemotherapy are less modifiable. This article summarizes acquired and modifiable risk factors in both pediatric and adult patients treated for cancer.
心脏性死亡是癌症幸存者继发于恶性肿瘤的主要死亡原因。肿瘤心脏病学领域致力于确定并在可能的情况下修正导致严重心脏发病率和死亡率的风险因素。许多癌症相关性心脏毒性的发展风险因素与心血管疾病的风险因素重叠,如高血压、肥胖、血脂异常和糖尿病等。这些风险因素通常是可修正的,而其他因素,如遗传、恶性肿瘤类型和化疗需求,则较难修正。本文总结了儿科和成人癌症患者的获得性和可修正风险因素。